LU92634I2 - Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl) - Google Patents

Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl) Download PDF

Info

Publication number
LU92634I2
LU92634I2 LU92634C LU92634C LU92634I2 LU 92634 I2 LU92634 I2 LU 92634I2 LU 92634 C LU92634 C LU 92634C LU 92634 C LU92634 C LU 92634C LU 92634 I2 LU92634 I2 LU 92634I2
Authority
LU
Luxembourg
Prior art keywords
vizamyl
flutemetamol
pharmaceutically acceptable
acceptable derivatives
derivatives
Prior art date
Application number
LU92634C
Other languages
English (en)
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Publication of LU92634I2 publication Critical patent/LU92634I2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LU92634C 2003-08-22 2015-01-14 Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl) LU92634I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses

Publications (1)

Publication Number Publication Date
LU92634I2 true LU92634I2 (fr) 2015-11-02

Family

ID=41568829

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92634C LU92634I2 (fr) 2003-08-22 2015-01-14 Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl)

Country Status (2)

Country Link
US (3) US8236282B2 (fr)
LU (1) LU92634I2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270800B2 (en) * 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
RU2324686C2 (ru) * 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
US8236282B2 (en) * 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
KR102349433B1 (ko) * 2015-11-27 2022-01-10 삼성전자주식회사 자이로스코프 센서를 제어할 수 있는 이미지 센서와 이를 포함하는 장치들
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
KR102051666B1 (ko) * 2017-12-07 2019-12-04 사회복지법인 삼성생명공익재단 아밀로이드 페트(pet) 영상을 이용한 알츠하이머 치매의 병기 측정 방법 및 장치
KR102649096B1 (ko) * 2021-11-23 2024-03-18 연세대학교 산학협력단 Pet 영상 변환 방법 및 이를 이용한 뇌질환 진단 방법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL126227C (fr) 1958-08-22
DE3148291A1 (de) 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
DE3307364A1 (de) 1983-03-02 1984-09-06 Hoechst Ag, 6230 Frankfurt Zweikomponenten-diazontypiematerial
DE3874187T2 (de) 1987-04-08 1993-04-08 Salutar Inc Nachweis fuer amyloidose und alzheimer'sche krankheit sowie reagens hierfuer.
US4933156A (en) 1987-04-08 1990-06-12 Salutar, Inc. Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor
GB9317949D0 (en) 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
GB9503946D0 (en) * 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
WO1997026919A2 (fr) 1996-01-24 1997-07-31 Warner-Lambert Company Methode d'imagerie de depots amyloides
WO1998017267A1 (fr) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions et methodes pour traiter les etats associes a un deficit osseux
AU5354398A (en) 1996-11-22 1998-06-10 Elan Pharmaceuticals, Inc. N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions compri sing same, and methods for inhibiting beta-amyloid peptide release and/or it s synthesis by use of such compounds
AU1089900A (en) 1998-06-30 2000-01-24 Kevin Mcclung Controlled-penetration projectile
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
RU2324686C2 (ru) 2000-08-24 2008-05-20 Юнивесити Оф Питсбэг ПРОИЗВОДНЫЕ ТИОФЛАВИНА, СВЯЗЫВАЮЩИЕ АМИЛОИД, СПОСОБ ОБНАРУЖЕНИЯ in vivo ОТЛОЖЕНИЙ АМИЛОИДА И СПОСОБ РАСПОЗНАВАНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА
WO2002051821A1 (fr) 2000-12-22 2002-07-04 Astrazeneca Ab Composes therapeutiques
CA2444214A1 (fr) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Inhibiteurs d'agregation de plaque amyloide et agents d'imagerie diagnostique
GB0229686D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
GB0229695D0 (en) 2002-12-20 2003-01-29 Amersham Plc Solid-phase preparation of 18F-labelled amino acids
US8236282B2 (en) * 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
DK1771208T3 (da) * 2004-07-02 2013-09-02 Univ Pittsburgh Anvendelse af thioflavin radiomarkerede derivater i amyloid billeddannelse til vurdering af anti-amyloide terapier

Also Published As

Publication number Publication date
US8236282B2 (en) 2012-08-07
US20140220590A1 (en) 2014-08-07
US20130004422A1 (en) 2013-01-03
US20100021388A1 (en) 2010-01-28
US9134328B2 (en) 2015-09-15
US8691185B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
LU92513I2 (fr) Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi)
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
LU93093I2 (fr) Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza)
LU92419I2 (fr) Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®)
LU92336I2 (fr) Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA)
LU93189I2 (fr) Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
LU91882I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU91883I2 (fr) Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®)
LU92326I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS)
LU92024I2 (fr) Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR)
LU91624I2 (fr) Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS®)
LUC00127I2 (fr) Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro )
LU91757I2 (fr) Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®)
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
LU93096I2 (fr) Evolocumab et ses dérivés pharmaceutiquement acceptables (repatha)
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður